NCT04917042View on ClinicalTrials.gov

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

February 14, 2025

Study Completion Date

January 31, 2026

Conditions
Peripheral Nerve Sheath Tumor
Interventions
DRUG

Tazemetostat

Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

32608

University of Florida, Gainesville

Sponsors

Collaborators (1)

Epizyme, Inc.
All Listed Sponsors
collaborator

Epizyme, Inc.

INDUSTRY

lead

University of Florida

OTHER